Publication:
Pulmonary endarterectomy in patients with antiphospholipid syndrome-associated chronic thromboembolic pulmonary hypertension

Simple item page
dc.contributor.authorKOCAKAYA, DERYA
dc.contributor.authorALİBAZ ÖNER, FATMA
dc.contributor.authorDİRESKENELİ, RAFİ HANER
dc.contributor.authorYILDIZELİ, BEDRETTİN
dc.contributor.authorİNANÇ, GÜZİDE NEVSUN
dc.contributor.authorsTaş S., Antal A., Durusoy A. F., Yanartaş M., Yıldız K., Olgun Yıldızeli Ş., Kocakaya D., Mutlu B., Alibaz-Öner F., Direskeneli H., et al.
dc.date.accessioned2023-05-16T06:42:47Z
dc.date.available2023-05-16T06:42:47Z
dc.date.issued2022-05-01
dc.description.abstractBackground: Antiphospholipid syndrome is an autoimmune disease characterized by the occurrence of venous and/or arterial thrombosis. Chronic thromboembolism is one of the known established pathogenesis of pulmonary hypertension, known as chronic thromboembolic pulmonary hypertension. Pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension. The aim of this study is to evaluate the efficacy and risk of pulmonary endarterectomy in patients with antiphospholipid syndrome-associated chronic thromboembolic pulmonary hypertension. Methods: Data were prospectively collected and retrospectively analyzed, for patients who underwent pulmonary endarterectomy between March 2011 and March 2020. Results: Seventeen patients (4 male and 13 female) were identified. Thirteen patients had primary antiphospholipid syndrome and 4 had secondary antiphospholipid syndrome. The mean age was 34.82 ± 10.07 years and the mean time interval between the diagnosis and surgery was 26.94 ± 17.35 months. Dyspnea on exertion was the main symptom in all patients. Seven patients had previous deep vein thrombosis, 5 patients had a history of recurrent abortions, and 2 patients had hemoptysis. Following surgery, mean pulmonary artery pressure decreased from 47.82 ± 13.11 mm Hg to 22.24 ± 4.56 mm Hg (P < .001), and pulmonary vascular resistance improved from 756.50 ± 393.91 dyn/s/cm−5 to 298.31 ± 132.84 dyn/s/cm−5 (P < .001). There was no in-hospital mortality with a mean follow-up of 75.29 ± 40.21 months. The functional capacity of all patients improved from 269.46 ± 111.7 m to 490 ± 105.34 m on a 6-minute walking test. Conclusions: Pulmonary endarterectomy is a safe and curative treatment in patients with antiphospholipid syndrome-associated chronic thromboembolic pulmonary hypertension. It has a favorable outcome by increasing the quality of life. A multidisciplinary experienced chronic thromboembolic pulmonary hypertension team is critical in the management of these unique patients
dc.identifier.citationTaş S., Antal A., Durusoy A. F., Yanartaş M., Yıldız K., Olgun Yıldızeli Ş., Kocakaya D., Mutlu B., Alibaz-Öner F., Direskeneli H., et al., "Pulmonary Endarterectomy in Patients with Antiphospholipid Syndrome-Associated Chronic Thromboembolic Pulmonary Hypertension.", Anatolian journal of cardiology, cilt.26, sa.5, ss.394-400, 2022
dc.identifier.doi10.5152/anatoljcardiol.2021.1138
dc.identifier.endpage400
dc.identifier.issn2149-2263
dc.identifier.issue5
dc.identifier.startpage394
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/35552176/
dc.identifier.urihttps://hdl.handle.net/11424/289374
dc.identifier.volume26
dc.language.isoeng
dc.relation.ispartofAnatolian journal of cardiology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectSağlık Bilimleri
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectClinical Medicine (MED)
dc.subjectAntiphospholipid syndrome
dc.subjectchronic thromboembolic pulmonary hypertension
dc.subjectpulmonary endarterectomy
dc.subjectoutcome
dc.subjectSYSTEMIC-LUPUS-ERYTHEMATOSUS
dc.subjectINTERNATIONAL CONSENSUS STATEMENT
dc.subjectCLASSIFICATION CRITERIA
dc.subjectANTIBODIES
dc.subjectANTICOAGULANT
dc.subjectMANAGEMENT
dc.subjectTHROMBOSIS
dc.subjectDIAGNOSIS
dc.subjectAntiphospholipid syndrome
dc.subjectchronic thromboembolic pulmonary hypertension
dc.subjectpulmonary endarterectomy
dc.subjectoutcome
dc.titlePulmonary endarterectomy in patients with antiphospholipid syndrome-associated chronic thromboembolic pulmonary hypertension
dc.typearticle
dspace.entity.typePublication
local.avesis.idf38741a1-ace5-42a8-be95-0af0d98f9044
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
local.indexed.atTRDIZIN
relation.isAuthorOfPublication2771cdd6-7c3b-45a8-89fe-a429a2950516
relation.isAuthorOfPublicatione995a136-8c56-4192-bebe-fe522b567ef1
relation.isAuthorOfPublication07a34d26-21f3-475d-bd36-152d6c659370
relation.isAuthorOfPublicationd6b68c67-eea7-4dc3-8688-e8cfbe3bbcd2
relation.isAuthorOfPublicationc963a17b-4775-4dd7-8db7-ea072cc49ef1
relation.isAuthorOfPublication.latestForDiscovery2771cdd6-7c3b-45a8-89fe-a429a2950516

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
4.pdf
Size:
1.58 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs